Zynerba Pharmaceuticals Inc ZYNE shares are trading lower by $8.50, or 56 percent, at $6.50 in Monday's session.
Before the open, the company announced top-line results from Phase 2 Star 1 trial of ZYN002 for treatment of adult epileptic patients with focal seizures didn't meet its primary endpoint.
See Also: What Zynerba's Flop Means For CBD Therapies And GW Pharmaceuticals
After a lower open, Zynerba had a brief bounce to $6.75 before continuing its move lower. So far, the ensuing decline has taken the stock to $5.93, but rebounded back into the mid-$6.00 handle. That low comes in just above March 2015 low ($5.75).
Its all-time low was made the month prior at $4.64.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.